Login
Companies $NRIX
$14.92 +$0.19 (1.29%) After hours
Nurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc.

nurixtx.com

What Do They Do?

Develops targeted protein-degrading drug candidates for patients with cancer and inflammatory diseases, and drug-discovery programs for biopharmaceutical partners.

Who Are Their Customers?

Biopharmaceutical companies work directly with Nurix through drug-discovery collaborations and licenses; Roche has an exclusive worldwide license to develop and commercialize bexobrutideg.

Do Revenues Turn Into Profits?

No. It lost $264.5M in FY2025.

Operating income, FY2025
−340% of revenue
▼ −34% (Loss) vs FY2024 (−$213M, −391%)
Net income, FY2025
−315% of revenue
▼ −37% (Loss) vs FY2024 (−$193.6M, −355%)
Free cash flow, FY2025
−314% of revenue
▼ −45% (Loss) vs FY2024 (−$181.9M, −333%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Aug 31, 2026
Revenue
▲ +8426%
vs $7.9M in Q3 FY2025
Net income
▲ Turned profitable
vs −$86.4M in Q3 FY2025
Collaboration revenue share of revenue vs 100.0% in Q3 FY2025
  • Jun 8, 2026 Nurix granted Roche a worldwide license for bexobrutideg Roche will pay $700.0 million upfront; they will share U.S. profits and losses, while Roche handles commercialization outside the United States.

A degrader-centered portfolio The older report described both protein lowering and protein elevation and included a cell-therapy program; the latest centers on targeted protein degraders and includes degrader-antibody conjugates in preclinical work.

An AI-integrated discovery platform The older report described a discovery platform built around ligase expertise and compound libraries; the latest describes DEL-AI as AI-integrated, with machine learning and automated chemistry.

An expanded collaboration roster The older report described collaborations with Gilead and Sanofi; the latest also names Pfizer as a drug-discovery partner.

Revenue over time
Collaboration revenue License revenue
$100M$50M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support